DDInter1789 DDInter927
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Thalidomide {u} (Compound) treats {v} (Disease) hematologic cancer
Thalidomide {u} (Compound) binds {v} (Gene) FGFR2
Thalidomide {u} (Compound) upregulates {v} (Gene) TGFBR2
Thalidomide {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Immunologically Active Molecule Activity
Thalidomide {u} (Compound) downregulates {v} (Gene) ARNT2
Thalidomide {u} (Compound) causes {v} (Side Effect) Myocardial ischaemia
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Astemizole
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Thalidomide (Compound) resembles Lenalidomide (Compound)
Thalidomide (Compound) treats hematologic cancer (Disease)
Thalidomide (Compound) binds FGFR2 (Gene)
Thalidomide (Compound) upregulates TGFBR2 (Gene)
Thalidomide (Compound) is included by Decreased Immunologically Active Molecule Activity (Pharmacologic Class)
Thalidomide (Compound) downregulates ARNT2 (Gene)
Thalidomide (Compound) causes Myocardial ischaemia (Side Effect)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Astemizole
Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine